Oxytocin and Vasopressin Levels and Related Factors in Adolescents with Social Phobia and Other Anxiety Disorders

Necati Uzun¹, Ömer Faruk Akça¹, İbrahim Kılıç², Tevfik Balcı³

Departments of ¹Child and Adolescent Psychiatry, ²Biochemistry, Necmettin Erbakan University, Meram School of Medicine, Konya, ³Department of Biochemistry, Niğde Ömer Halisdemir University Training and Research Hospital, Niğde, Turkey

Objective: This study aimed to determine whether a difference exists in plasma oxytocin and vasopressin levels among social anxiety disorder, other anxiety disorders, and healthy control groups in adolescents. The relationship between several psychiatric variables (i.e., state and trait anxiety, social anxiety, childhood trauma, and behavioral inhibition) and oxytocin or vasopressin levels were also investigated in adolescents with anxiety disorders.

Methods: The study included three groups of adolescents: social anxiety disorder (n = 29), those with other anxiety disorders (n = 27), and the control group (n = 28). The participants filled out self-report scales to determine various psychological variables. Oxytocin and vasopressin levels were determined from the blood samples of the participants.

Results: The oxytocin levels did not show a significant difference between the social anxiety disorder group and the other anxiety disorders group. However, the oxytocin levels were significantly higher in the social anxiety disorder and other anxiety disorders groups than in the control group. The vasopressin levels did not show a significant difference among the groups. According to the hierarchical regression analysis, the state and trait anxiety levels predicted oxytocin in opposite directions. Oxytocin showed positive and negative relationship with trait and state anxiety respectively. No predictive factors were found for the vasopressin levels.

Conclusion: We found that the oxytocin levels of adolescents with social anxiety disorder were not different from those of adolescents with other anxiety disorders. Further studies can improve our knowledge of the relationship among anxiety disorders and oxytocin or vasopressin.

KEY WORDS: Anxiety disorders; Behavioral inhibition; Oxytocin; Social phobia; Vasopressin.

INTRODUCTION

Anxiety disorders are frequently seen in children and adolescents, and they cause significant impairments in various areas of their life, including school achievement, social life, and overall quality of life [1,2]. In the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5), anxiety disorders in children and adolescent are classified as social anxiety disorder (SoPh), generalized anxiety disorder (GAD), separation anxiety disorder (SAD), panic disorder (PD), selective mutism, and agoraphobia [3]. The etiology of anxiety disorders is not well known, but various factors may play a role, including genetic, temperamental (i.e., inhibitory temperamental traits), environmental (i.e., parental and family attitudes), and some biological factors [4]. Studies investigating the relationship between anxiety disorders and neurobiological mechanisms indicate that various neuropeptides, neurohormones, and brain structures (i.e., serotonin, dopamine, and the amygdala) may have a role in the etiology of such disorders [5,6]. Although the complex interactions between psychological and biological systems are suspected in this etiology, the exact neurobiological mechanisms underlying these diseases are currently unknown. Recent studies indicate a possible relationship between anxiety disorders and some neuroendocrine hormones, such as oxytocin (OXT) and vasopressin (AVP) [7-9]. However, to date, there have been in-
Neumann et al. reported that the HPA axis was sup-
dicate that OXT has an anxiolytic effect [14]. For example, pituitary adrenal (HPA) axis [13]. Most of these studies in-
to the central nervous system, including the hypothalamic ic roles in fear and anxiety behaviors in systems related
studies. Animal studies demonstrate that OXT plays crit-
al link between OXT and anxiety disorders, and remark-
able data were obtained on this relationship in preclinical studies. Animal studies demonstrate that OXT plays crit-
cial roles in fear and anxiety behaviors in systems related to the central nervous system, including the hypothalamic

Kirsch [16] and Suzuki et al. [13] reported that OXT has regulatory effects on fear, social stress, and anxiety, normalizing amygdala activity during stress-causing social behaviors and fear and suppressing the HPA axis to exhibit anxiolytic effects. Supporting the possible anxiolytic effect of OXT, a recent study reported a high level of OXT associated with high social anxiety symptoms in patients with SoPh [9]. However, some studies have found results to the contrary. In a study conducted on adult subjects with SoPh, a positive relationship was reported between the severity of anxiety symptoms and the OXT level, despite the lack of a significant difference between the subjects with SoPh and the controls [8]. However, in their subsequent study, the authors reported a conflicting finding, namely that low levels of peripheral blood OXT were associated with SoPh [17]. Therefore, no consensus has yet been reached on this topic. Moreover, research examining the relationship between OXT and anxiety disorders in humans has been conducted mostly in adults. We have very limited knowledge about this relationship in adolescents. To the best of our knowledge, only one study investigated this relationship in adolescents, reporting that salivary OXT levels and anxiety symptoms have a negative correlation [18], a finding that contradicts the above-mentioned hypothesis that OXT has a positive rela-
tionship with the anxiety level. Based on the contradictory findings in relation to adolescents and in light of the fact that anxiety disorders may arise and manifest differently in adults and adolescents [19], the first aim of the present study was to explore the relationship between OXT and anxiety disorders in adolescents.

Further, the relationship of OXT with different types of anxiety disorders is unknown, since studies on this subject generally investigate SoPh or SAD. However, it has not been investigated whether these anxiety disorders differ in terms of their relationship with OXT. In SoPh, the subjects exhibit fear of social situations, which has shown to be associated with the OXT system [20,21]. As OXT is known to be an important molecule in social relationships, discrepancies between studies may be due to differences between other anxiety disorders and SoPh. To our knowl-

differences of OXT levels in males and females is not clear. In a preclinical study, it has been shown that OXT receptor expression is higher in males than females [23]. Additionally, a study in humans found that women had higher OXT levels than men [24]. However, the relationship between OXT levels and behavior in terms of gender varies considerably between species. It is also suggested that gender differences in behavior are not related to structural changes in the OXT system [25].

AVP is classically known for its role as a hormone involved in homeostasis. Although its association with psychi-

Sufficient data to confirm this relationship.

OXT and AVP are synthesized from the magnocellular neurons of the supraoptic and paraventricular nuclei in the hypothalamus and transported to the posterior pituitary gland to be released [10,11]. OXT is well known for its physiological role as a hormone involved in lactation and uterine contractions [12]. Recent studies have shown that OXT also has significant effects on attachment, social interaction, stress management, social cognitive function, and mood [10]. Some studies have investigated the potential link between OXT and anxiety disorders, and remark-

Kirsch [16] and Suzuki et al. [13] reported that OXT has regulatory effects on fear, social stress, and anxiety, normalizing amygdala activity during stress-causing social behaviors and fear and suppressing the HPA axis to exhibit anxiolytic effects. Supporting the possible anxiolytic effect of OXT, a recent study reported a high level of OXT associated with high social anxiety symptoms in patients with SoPh [9]. However, some studies have found results to the contrary. In a study conducted on adult subjects with SoPh, a positive relationship was reported between the severity of anxiety symptoms and the OXT level, despite the lack of a significant difference between the subjects with SoPh and the controls [8]. However, in their subsequent study, the authors reported a conflicting finding, namely that low levels of peripheral blood OXT were associated with SoPh [17]. Therefore, no consensus has yet been reached on this topic. Moreover, research examining the relationship between OXT and anxiety disorders in humans has been conducted mostly in adults. We have very limited knowledge about this relationship in adolescents. To the best of our knowledge, only one study investigated this relationship in adolescents, reporting that salivary OXT levels and anxiety symptoms have a negative correlation [18], a finding that contradicts the above-mentioned hypothesis that OXT has a positive rela-

...
on the regulation of anxiety-like and emotional behavior [29]. Particularly, OXT exerts anxiolytic and anti-depressive effects, whereas AVP mainly increases anxiety and depression-related behaviors. Research on the mechanisms of these neuropeptides has demonstrated that OXT and AVP modulate anxiety responses in the amygdala of rats in opposite ways, resulting in an OXT/AVP balance [30-32]. There are also conflict results from studies with intranasal AVP. In a study conducted in rats, it was shown that intranasal AVP has no effect on social recognition and short-term recognition memory [33]. On the other hand, in another study conducted in male adults, it was found that intranasal AVP in individuals with neurotic traits increased responses in various brain regions to negative social interactions and increased insula response to positive social interactions [26]. Considering the literature, mostly based on animal studies, reporting a possible relationship between OXT, AVP, and anxiety disorders, we aimed to explore this relationship in the context of SoPh, since both of these molecules have a clear association with social interaction. Therefore, we aimed to compare the OXT and AVP levels of the adolescents with SoPh, adolescents with other anxiety disorders, and healthy adolescents. We have hypothesized that the OXT and AVP levels of adolescents with SoPh and those with other anxiety disorders would be different, and that the levels of OXT and AVP in these two groups would be different from those of healthy adolescents.

Despite the prevalence of studies focusing on the relationship between anxiety and OXT, to our knowledge, the relationships between OXT and various psychological factors, which are known to be associated with anxiety (i.e., childhood trauma) have not been studied sufficiently. Only one adult study reported lower OXT concentrations in the cerebrospinal fluid of women who experienced early-life abuse [34]. In addition, the relationship between OXT and some anxiety-related constructs (i.e., behavioral inhibition, state and trait anxiety) have not been studied yet. State anxiety and trait anxiety are different concepts, reflecting different mechanisms and features. State anxiety is an emotional state characterized by subjective thoughts and feelings related to worry, apprehension, tension, and nervousness; it varies in intensity and fluctuates over time. In contrast, trait anxiety is an individual personality trait, characterized by a tendency to attend to, experience, and report fears, worries, and anxiety, as reflected in the frequency with which anxiety states have been experienced in the past and the probability that state anxiety reactions will be experienced in the future [35]. These constructs are known to affect various psychological variables by diverse routes [36]. One study showed a positive relationship between state anxiety and OXT [37], however, relationships between OXT and state and trait anxiety in the same sample were not previously studied. Considering the diversities between these constructs, we have hypothesized that the relationship between OXT and state and trait anxiety are likely to be different. In addition, considering that anxiety is closely related to behavioral inhibition and childhood trauma [34], we have hypothesized that these constructs are also likely to be associated with OXT in adolescents with anxiety disorders.

**METHODS**

**Participants**

The study groups were recruited from the outpatient clinic for child and adolescent psychiatry at a university hospital. They were treatment-naïve adolescents aged 12–18 years who were diagnosed with SoPh, GAD, SAD, or PD, based on the DSM-5 criteria. The exclusion criteria were the presence of major physical, endocrinological, or neurological diseases, autism spectrum disorder, psychotic disorder, bipolar disorder, substance use disorder, severe head trauma, and intellectual disability—evaluated via clinical interview. Patients who had used psychotropic drugs within the previous six months or smoked, alcohol and other substance used within the six months prior to admission were also excluded from the study. The control group consists of healthy adolescents between the ages of 12–18, who do not have any known disease and who meet the inclusion and exclusion criteria and volunteer to participate in the study. No other specific criteria considered except for the inclusion and exclusion criteria. The psychiatric evaluation of the control group was carried out one day before blood samples were taken. The same inclusion and exclusion criteria were applied to the control group. Moreover, the subjects who had any anxiety disorder in the control group were excluded from the study. The Schedule for Affective Disorders and Schizophrenia for School-Aged Children, Present and Lifetime Version (K-SADS-PL) was applied for the patients and control subjects by an experienced child and adoles-
The diagnoses of SoPh, GAD, SAD, and PD were made according to the DSM-5 criteria [39]. The K-SADS-PL is a semi-structured interview form developed by Kaufman et al. to identify the past and present mental disorders of children and adolescents [40]. The K-SADS-PL is implemented through face-to-face interviews with parents and the child or young person, and all data are finalized by evaluating the information received from the sources (parents, children, and schools). If a discrepancy exists in the data obtained from different sources, the clinician uses his/her clinical judgment to settle the issue. The validity and reliability of this interview form for our nation were established [38]. The study for adapting the K-SADS to DSM-5 was also conducted [39].

The study was approved by the local ethics committee of the university (no. 2016/505) and all the procedures were in accordance with the Declaration of Helsinki and local laws and regulations. The participants and their parents gave their written informed consent after the investigators explained the purpose and course of the study. Oral assent was also obtained from all subjects. In the patient groups, 60 children were approached, but four were excluded on the basis of the exclusion criteria. In the control group, 36 children were approached, but eight were excluded.

**Procedures**

To determine the adolescents’ depression and anxiety levels, the participants completed the Children’s Depression Inventory (CDI) and the State-Trait Anxiety Inventory for Children (STAIC) [41,42]. The adolescents were also asked to complete the Childhood Trauma Questionnaire (CTQ) to measure their childhood trauma and the Social Anxiety Scale for children (SAS) to evaluate their social anxiety levels [43,44]. In addition, the adolescents filled out the Behavioral Inhibition System and Behavioral Activation System Questionnaire (BIS/BAS) to assess their behavioral inhibition (BI) levels [45]. The reliability and the validity of all questionnaires were previously established for the Turkish population. All psychiatric assessments, including the diagnostic interview and self-report evaluations, were administered to the subjects in a separate quiet room designed for psychiatric assessment. The day after completion of the psychiatric assessments, the participants were invited to the hospital for a phlebotomy procedure. After 30 minutes of acclimatization, peripheral venous blood samples for OXT and AVP were drawn from an antecubital vein in a sitting position between 8:00 AM and 10:00 AM. Subjects were requested to fast for 12 hours and to avoid heavy exercise prior to the blood sampling. In this way, possible changes induced by circadian variations or by previous meals were minimized. The participants had not seen the phlebotomy room before the procedure. Blood samples were taken by a licensed phlebotomist in the phlebotomy room, in the presence of the interviewer (NU). The parent escorting the participant was requested to wait in a different room. Psychiatric evaluation and blood sampling of the control group were carried out in a similar manner.

The blood samples of the participants and the controls were extracted and collected in appropriate tubes. The tubes were centrifuged at 4,000 rpm for 5 minutes at 4°C. Then, the plasma was stored at −80°C in Eppendorf tubes until analysis. Enzyme-linked immunosorbent assay (ELISA) kits were used for the plasma analyses of OXT (Cayman, Ann Arbor, MI, USA) and AVP (Elabscience, Wuhan, China). The plasma levels of OXT and AVP were measured using ELISA kits following the manufacturer’s protocols. The patient and control samples were run together in the same plates.

**Children’s Depression Inventory**

The CDI is a self-assessment scale used to measure the level of depression in children and adolescents [46]. It consists of 27 items and can be used with individuals aged 6 – 17 years. Each item of the scale contains three statements designed to evaluate the state of the individual in the previous two weeks. The total scores obtained from the statement points constitute the total score of the scale. The higher the total score, the more severe the depression level. The highest score on the scale is 54, and the cut-off point is 19. In our study, Cronbach’s coefficient alpha for CDI was 0.85, which was very similar to a previously reported study with adolescents (0.86) [47]. This scale was adapted for our nation and Cronbach’s alpha for CDI in our nation was previously reported as 0.80 [41].

**State-Trait Anxiety Inventory for Children**

The STAIC is used to measure anxiety levels in children [48]. Developed by Spielberger, this scale has two multiple-choice subscales with 20 questions for state (CSAI) and trait (CTAI) anxiety. Each item is scored 0, 1, or 2, ac-
According to the severity of the indication, State anxiety can change according to external factors and defines the anxiety that the individual feels in certain circumstances at a certain time. Trait anxiety describes how the individual feels in general and reflects the individual’s general anxiety predisposition. In a study conducted in adolescents, Cronbach’s alpha of total STAIC was 0.91 [49]. Our sample demonstrated similar values (CSAI: 0.92, CTAI: 0.91). The validity and reliability study for our population was conducted. Cronbach’s coefficient alpha for CSAI and CTAI in our nation was reported previously as 0.82 and 0.81, respectively [42].

**Childhood Trauma Questionnaire**

The CTQ was developed by Bernstein et al. [50] to investigate the trauma experiences of adolescents. It has 40 items in a five-point Likert scale. Higher scores indicate a higher frequency of childhood traumatic experiences. The CTQ has three subscales: emotional abuse and emotional neglect, physical abuse, and sexual abuse. A previous adolescent study reported Cronbach’s alpha for CTQ as 0.97 [51], compared with 0.87 in our study. The validity and reliability of the CTQ for our nation was established with a high Cronbach’s alpha value (0.96) [43].

**Social Anxiety Scale for Children**

The SAS for children was developed by La Greca and Stone [52] to assess children’s social anxiety levels. It consists of 18 questions and evaluates two components of social anxiety, namely fear of negative evaluation and distress and discomfort in the social environment. Cronbach’s coefficient alpha for SAS was 0.96 in our study. The validity and reliability study for our nation was conducted and reporting a Cronbach’s alpha value of 0.81 [44].

**Behavioral Inhibition System and Behavioral Activation System Questionnaire**

The BIS/BAS was developed by Carver and White [53]. The behavioral inhibition subscale and the behavioral activation heading consist of a total of 4 subscales and 24 items: there is a behavioral inhibition-related and there are three behavioral activation-related scales (reward responsiveness, drive, fun seeking). There are seven items on the behavioral inhibition subscale, four on the entertainment-seeking subscale, five on the susceptibility subscale, and four on the impulsive subscale. The participants evaluate themselves on a four-point Likert scale for each item (1: I totally agree, 2: I slightly agree, 3: I slightly disagree, 4: I do not agree at all). Although there are 24 items in the scale, evaluation is made over 20 items. In scoring, all items except items 2 and 22 are calculated by reversing. Cronbach’s coefficient alpha for BIS/BAS was 0.76 in our study. The validity and reliability study for our nation was conducted, and we used the behavioral inhibition subscale of the BIS/BAS in this study, which was reported to have a Cronbach’s alpha value of 0.69 [45].

**Statistical Analysis**

Statistical analyses were performed with SPSS 20.0 statistical software (IBM Co., Armonk, NY, USA). The variables were presented as a number (n), percentage (%), mean ± standard deviation, or frequency. All of the variables were checked for normality using the Kolmogorov–Smirnov test. MANOVA tests were used to compare the differences in the three groups (SoPh, other anxiety disorders, and control) in terms of the demographic and clinical characteristics. To compare the OXT and AVP levels of the groups, a multivariate analysis of covariance (MANCOVA) was conducted to avoid the risk of type II errors related to the multiple testing effect and to control for possible confounding factors (i.e., age and sex). After determining that the MANCOVA test yielded a significant difference among the groups, a one-way analysis of covariance (ANCOVA) was separately performed on the outcome variables. Before the MANCOVA and ANCOVA tests, variables showing non-normal distributions (i.e., age and OXT) were logarithmically transformed. Bonferroni post hoc tests were conducted, with corrections for multiple testing. A new group (a whole anxiety disorder group) was formed, including the participants with SoPh and other anxiety disorders, to conduct the correlation and regression analyses. Pearson or Spearman’s correlation analyses were used for variables showing normal or non-normal distribution features, respectively, to determine the association between the clinical and psychological variables in the whole anxiety disorder group. A hierarchical regression analysis was conducted to determine the variables predicting the OXT and AVP levels in the same group. Possible predicting variables were put in the analysis step by step, and the coefficient of determination (R²) changes were explored to determine the steps, resulting in an incremental contribution to the analysis.
The significance level of the 95% confidence interval in the analyses was set to less than 0.05, except for the correlation analyses. To avoid the type II error related to multiple testing, the p value was set to less than 0.01 for the correlation analyses.

RESULTS

The final study population consisted of 29 adolescents with SoPh, 27 with other anxiety disorders, and 28 healthy controls. In the other anxiety disorders group, there were 16 adolescents with GAD, 9 adolescents with SAD and 2 adolescents with PD. Table 1 presents and compares the descriptive data and the clinical variables of the study groups. As shown in the table, no significant between-group difference was found for age or gender distribution of the groups. CDI, CSAI, CTAI, and BIS/BAS scores were statistically significantly higher in SoPh and other anxiety groups compared to the control group. However, no statistically significant difference was found between SoPh and other anxiety groups. SAS scores were statistically significantly higher in SoPh group than other anxiety group and control group. Also, SAS scores were statistically significantly higher in other anxiety group compared to the control group. There was no statistically significant difference between the study groups in terms of CTQ scores.

OXT levels were 211.4 ± 69.1 pg/ml in the SoPh group, 216.2 ± 75.9 pg/ml in the other anxiety disorders group and 166.2 ± 52.7 pg/ml in the control group. AVP levels were 38.1 ± 12.6 pg/ml in the SoPh group, 39.4 ± 19.6 pg/ml in the other anxiety disorders group and 50.6 ± 25.4 pg/ml in the control group. MANCOVA analysis yielded that there were significant differences among the groups (Pillai’s Trace V = 0.198, F [2, 79] = 4.34, p = 0.002, np² = 0.099) in terms of OXT and AVP. Separate univariate ANCOVA was conducted after being adjusted for age and sex, and the OXT and AVP levels of the three groups were compared. The analyses showed significantly higher OXT levels in the SoPh and other anxiety disorder groups compared to the controls (F [2, 81] = 5.24, p = 0.007, np² = 0.117); (Fig. 1) however, the AVP levels were not significantly different among groups (F [2, 81] = 2.83, p = 0.065, np² = 0.067) (Fig. 2). Averages of

---

**Table 1.** Demographic and clinical characteristics of the participants

| Variables         | Social anxiety disorder (n = 29) | Other anxiety disorders (n = 27) | Control group (n = 28) | Statistical analysis | Post-hoc analysis* |
|-------------------|----------------------------------|----------------------------------|------------------------|----------------------|--------------------|
|                   | Sex (M/F)                        |                                  |                        | χ²                   | F                  | p value            |                      |
|                   | 11 (38/18)                       | 13 (48/14)                       | 13 (46/15)             | 0.689                | 2.84               | 0.06               | 0.709               |
|                   | Age (years)                      | 14.74 ± 1.9                      | 13.77 ± 1.5            | 15.04 ± 1.7          | 11.6 ± 5.78        | 9.505              | < 0.001             |
|                   | CDI                              | 19.8 ± 8.37                      | 17.5 ± 8.22            | 11.6 ± 5.78          | 9.505              | < 0.001             | 1 > 3, 2 > 3        |
|                   | SAS                              | 68.03 ± 9.22                     | 39.23 ± 12.86          | 27.21 ± 7.38         | 117.6              | < 0.001             | 1 > 2 > 3           |
|                   | CTQ                              | 61.62 ± 17.02                    | 61.30 ± 15.29          | 56.85 ± 14.69        | 120.5              | < 0.001             | 1 > 2 > 3           |
|                   | CSAI                             | 42.77 ± 9.5                      | 45.03 ± 10.3           | 34.57 ± 10.59        | 9.674              | < 0.001             | 1 > 3, 2 > 3        |
|                   | CTAI                             | 41.22 ± 9.27                     | 40.76 ± 10.15          | 32 ± 9.29            | 9.044              | < 0.001             | 1 > 3, 2 > 3        |
|                   | BIS/BAS-BI                       | 22.11 ± 2.42                     | 22.69 ± 2.94           | 20.21 ± 3.37         | 5.402              | 0.006               | 1 > 3, 2 > 3        |

Values are presented as number (%) or mean ± standard deviation.

CDI, Children’s Depression Inventory; SAS, Social Anxiety Scale for Children; CTQ, Childhood Trauma Questionnaire; BIS/BAS-BI, Behavioral Inhibition System and Behavioral Activation System Questionnaire Behavioral Inhibition Subscale; CSAI, State Anxiety Inventory for Children; CTAI, Trait Anxiety Inventory for Children.

*1: social anxiety disorder, 2: other anxiety disorders, 3: control group.
the OXT and AVP levels are given in Table 2.

As the SoPh and other anxiety groups were similar in terms of both OXT and AVP levels, we combined these groups to conduct further (correlation and hierarchical regression) analyses. Thus, we investigated the relationship between the psychological variables and the OXT and AVP levels in this new group, which comprised SoPh and other anxiety disorder groups (n = 56). According to the correlation analyses, no correlations were observed between the psychological variables and the OXT and AVP levels (Table 3). The psychological variables predicting the OXT levels were determined using a hierarchical regression analysis. As shown in Table 4, only the last step of the analysis (including CSAI and CTAI) was statistically significant and made an incremental contribution to the analysis ($R^2 = 0.27, p = 0.04, R^2$ change $= 0.13, p = 0.02$), indicating that only CSAI (negatively) and CTAI (positively) predicted OXT levels of the subjects with anxiety disorders. The same analysis was performed to determine the factors predicting the AVP levels of the same group. However, no predictive factors were found in the regression analysis ($p = 0.44$).

**DISCUSSION**

This study was the first to investigate the plasma OXT and AVP levels in adolescents with SoPh alone, those with other anxiety disorders (SAD, GAD, and PD), and healthy controls to elucidate the possible roles of these neuroendocrine hormones in the neurobiological background of anxiety disorders. The analyses demonstrated
Table 4. Factors predicting oxytocin levels according to the hierarchical regression analysis

| Variables | B    | SE    | t     | p value | p change | R² change | F change |
|-----------|------|-------|-------|---------|----------|-----------|----------|
| (Constant)| 343.767 | 76.658 | 4.484 | 0.000 | 0.153 | 0.068 | 1.947 |
| Sex       | −26.000 | 19.400 | −1.340 | 0.186 |        |          |          |
| Age       | −6.219 | 5.260 | −1.182 | 0.242 |        |          |          |
| (Constant)| 341.700 | 76.428 | 4.471 | 0.000 | 0.251 | 0.024 | 1.348 |
| Sex       | −36.593 | 21.381 | −1.711 | 0.093 |        |          |          |
| Age       | −6.850 | 5.271 | −1.300 | 0.199 |        |          |          |
| CDI       | 1.502 | 1.294 | 1.161 | 0.251 |        |          |          |
| (Constant)| 473.476 | 123.994 | 3.819 | 0.000 | 0.418 | 0.051 | 0.962 |
| Sex       | −33.902 | 21.468 | −1.579 | 0.121 |        |          |          |
| Age       | −7.074 | 5.339 | −1.325 | 0.191 |        |          |          |
| CDI       | 1.759 | 1.354 | 1.298 | 0.200 |        |          |          |
| SAS       | 0.134 | 0.541 | 0.247 | 0.806 |        |          |          |
| CTQ       | −0.098 | 0.617 | −0.158 | 0.875 |        |          |          |
| BIS/BAS-BI| −6.181 | 3.700 | −1.670 | 0.101 |        |          |          |
| (Constant)| 452.560 | 117.236 | 3.860 | 0.000 | 0.023 | 0.127 | 4.085 |
| Sex       | −37.999 | 20.876 | −1.820 | 0.075 |        |          |          |
| Age       | −5.320 | 5.532 | −0.962 | 0.341 |        |          |          |
| CDI       | 2.455 | 1.627 | 1.509 | 0.138 |        |          |          |
| SAS       | −0.272 | 0.533 | −0.510 | 0.612 |        |          |          |
| CTQ       | −0.065 | 0.593 | −0.110 | 0.913 |        |          |          |
| BIS/BAS-BI| −3.848 | 3.603 | −1.068 | 0.291 |        |          |          |
| CTAI      | 3.827 | 1.716 | 2.231 | 0.030 |        |          |          |
| CSAI      | −4.553 | 1.657 | −2.748 | 0.008 |        |          |          |

Variable: Oxytocin.
SE, standard error; CDI, Children’s Depression Inventory; SAS, Social Anxiety Scale for Children; CTQ, Childhood Trauma Questionnaire; BIS/BAS-BI, Behavioral Inhibition System and Behavioral Activation System Questionnaire Behavioral Inhibition Subscale; CSAI, State Anxiety Inventory for Children; CTAI, Trait Anxiety Inventory for Children.

Comparison studies conducted on clinical samples on the OXT levels of anxiety disorders are limited, and they reveal inconsistent findings. Hoge et al. [8] reported two contrasting findings in different adult studies: one found that individuals with SoPh and the control group did not differ, whereas the other found that low levels of peripheral blood OXT were associated with SoPh [17]. Despite the discrepancies in the results of comparison studies, OXT is used for anxiolytic purposes, based on the findings of animal studies, thus indicating that OXT has anxiolytic effects by regulating the hypothalamus–pituitary axis system [15,54-56]. The OXT receptor system is activated by anxiogenic and stressful stimuli, as reflected by the stimulated release of peripheral and intracerebral OXT. For example, exposure to novelty, forced swimming, or social defeat increased OXT release into rats’ blood [57]. On the other hand, the anxiogenic effects of OXT were reported in some human studies [58,59]. Some authors claimed that these inconsistent findings arose from context-dependent factors [60]. In contrast to the suggestion that OXT has an anxiolytic effect, we found that the subjects with anxiety disorders had higher OXT levels than the controls. This finding can be explained by the notion...
that the OXT receptor system can be regulated by the stress response system. Specifically, because of the anxiety or stress that these subjects experienced, which could be an adaptation strategy, the OXT receptors could have downregulated and resulted in an increase in OXT levels. Supporting this hypothesis, the OXT receptor system has been shown to be epigenetically regulated according to the attachment style [61]. Moreover, the OXT receptor system is epigenetically downregulated in rhesus monkeys with early maternal deprivation [62].

However, the existing literature is based on adult studies and, to our knowledge, research on the relationship between OXT and anxiety disorder in adolescents is very limited. As mentioned in the introduction section, only one study reported a negative correlation between OXT and anxiety levels [18], which is partially compatible with our finding that OXT is negatively predicted by state anxiety. We suggest that researchers bear in mind the previous contradictory findings in adolescents and our finding that OXT has a variable relationship with state and trait anxiety.

The inconsistent findings in the literature on the relationship between OXT and anxiety have been attributed to the unstable and changeable nature of OXT. It is well known that any physical or mental stress changes OXT quickly. To minimize this effect, we completed the psychiatric evaluations one day prior to the phlebotomy procedure. However, all psychiatric evaluation and phlebotomy procedures were conducted in the psychiatry clinic of a hospital and it was the first experience of being in a psychiatry clinic for most of our subjects. This situation may, of itself, have caused stress and have slightly affected the results of the study.

OXT is known to be involved in several psychological concepts (i.e., attachment, trust, social reward, stress, depression, and anxiety) [10]. Although some relationships between OXT and anxiety disorders have been discovered, the findings in the literature are not consistent. Moreover, the differences between SoPh and other anxiety disorders are not known. We hypothesized a difference between SoPh and other anxiety disorders in terms of OXT levels, as SoPh is characterized by attentional biases focused on fear of social situations [63], which is not the focus of other anxiety disorders. On the basis of the literature indicating that OXT is known to enhance social cognition [54], which may be impaired among individuals with SoPh [64], we considered SoPh to differ in terms of OXT levels because the frightening situations are the social conditions, contrary to other anxiety disorders that do not include a fear of a social situation. Although the OXT levels of the SoPh group were higher than those of the controls, the SoPh group was similar to the other anxiety disorders group in terms of OXT levels. Moreover, the correlation and regression analyses revealed no relationship between the severity of SoPh symptoms and OXT levels. According to the findings of this study and in contrast to our second hypothesis, we assume that OXT is related to any fear in anxiety disorders, rather than fear of a social situation.

Studies focusing social relationships and trust in investigating the role of OXT on emotions have not reported any contradictory results on the OXT levels and the state and trait anxiety concepts, which indicate momentary and sustained anxiety, respectively. Our study is the first to indicate opposing ways to predict OXT levels for the state and trait anxiety levels. Limited studies investigated the relationships between both state and trait anxiety and OXT. For example, Lawson analyzed the relationships between trait and state anxiety levels and OXT levels in subjects with anorexia nervosa before and after eating and reported a positive relationship between OXT levels and trait anxiety and pre- and post-eating state anxiety [65].

However, the results of the regression analyses of the present study should be interpreted with caution, since highly correlated factors were put into the analyses as co-variates (i.e., depression, state and trait anxiety) which could have resulted in a suppression effect. Although the relationship between state and trait anxiety and depression is well known—and found in the correlation analyses of our study, as expected—we conducted regressions to see the univariate effects of these variables on OXT and AVP. We conducted a separate regression analysis including only age, gender, and state and trait anxiety levels to test the suppression effect of state and trait anxiety on OXT levels ($R^2 = 0.22, p = 0.013$) and found that OXT was still negatively predicted by state anxiety ($B = -4.2, p = 0.007$), and positively predicted by trait anxiety ($B = 4.6, p = 0.005$). This finding supports the notion that state and trait anxiety act as suppressors for each other in predicting OXT levels. On the other hand, since the $R^2$ of the regression analysis is not particularly high (0.27), we think that the suppression effect is not substantial.
Our findings did not reveal any relationship between OXT levels and the childhood trauma and behavioral inhibition levels of the subjects with anxiety disorders. Studies have reported inconsistent results on the relationship between OXT levels and childhood trauma [34,60]. In a recent study, childhood trauma was not related to plasma OXT levels but was negatively correlated with OXT receptor protein expressions in peripheral blood mononuclear cells [66]. This study indicates that the OXT system, rather than plasma levels, can be changed in the receptor regulation process. Furthermore, because the childhood trauma levels of our sample were not sufficiently high in our study, their effect on the OXT level may have not been so explicit. This issue should be elucidated in future studies.

The AVP levels did not show any difference among the groups in the comparison analysis and were not related to any psychological variable, according to the regression analysis. However, although the difference is not statistically significant in the dual comparisons, it can be seen that the controls had a higher level of AVP than the anxiety disorder groups (50 vs. 38 and 39 pg/ml). The non-significant result may be related to the small sample size, which could have hampered the statistical analyses.

Although many animal studies have indicated that AVP has an anxiogenic effect [28] contrary to our findings, human studies on this topic are limited. The explanation for these findings may be similar to that for the findings obtained from the comparison analysis of the OXT levels in the present study. Specifically, an upregulation in the AVP receptors of the subjects with anxiety could have resulted in lower levels of AVP. Supporting the hypothesis, the AVP gene expression could be changed by stress in rats [67]. Further studies with a larger sample could yield more informative data on this topic.

The present study has several limitations. First, our study sample was small, and we evaluated the psychological variables using self-reporting scales. Secondly, OXT levels may present high variability within the same subject. For this reason, this condition should be taken into consideration when evaluating the results. However, this is a common limitation due to the measurement method in studies on OXT. Also, since the BIS/BAS and SAS have been validated in adults and children respectively, and no validity studies conducted in adolescents, we had to rely on these scales. On the other hand, the menstrual histories and estradiol levels which affects OXT levels of the female participants were not evaluated in our study. Finally, participants completed the scales one day before the phlebotomy procedure, which may have given rise to contradictory relationships between CSAI and CTAI. However, since our study design did not contain an intervention to measure the effect of an anxiogenic condition on OXT or AVP, but instead aimed to test the relationship between these variables in a non-stressful setting, we deliberately scheduled the exercise of completing the scales before the phlebotomy to avoid the traumatic (and possibly anxiogenic) effect of the procedure.

In conclusion, we found that the OXT levels of adolescents with SoPh were not different from those of adolescents with other anxiety disorders. However, the OXT levels of all anxiety disorders were higher than those of the healthy controls. The OXT levels were predicted by the state and trait anxiety levels in opposite directions. Moreover, we evaluated the AVP levels of the subjects but could not find any significant difference among the groups nor a significant relationship in the regression analysis of the anxiety group. Further studies with a larger sample can improve our knowledge of the relationship among anxiety disorders, OXT, and AVP.

Funding

Funding for this study was provided by a grant from the Scientific Research Project Coordination Unit of Necmettin Erbakan University (Project no. 161518023).

Acknowledgments

We would like to thank our participants and their parents for taking part in this study.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Author Contributions

Conceptualization: Necati Uzun, Ömer Faruk Akça, İbrahim Kılınc. Data curation: Necati Uzun, Tevfik Balci. Funding acquisition: Necati Uzun, Ömer Faruk Akça. Methodology: Necati Uzun, Ömer Faruk Akça, İbrahim Kılınc. Formal analysis: Ömer Faruk Akça. Investigation: İbrahim Kılınc. Writing – original draft: Necati Uzun. Writing – review & editing: Ömer Faruk Akça.
REFERENCES

1. Lipsitz JD, Schneier FR. Social phobia. Epidemiology and cost of illness. Pharmacoeconomics 2000;18:23-32.
2. Wittchen HU, Fuetsch M, Sonntag H, Müller N, Liebowitz M. Disability and quality of life in pure and comorbid social phobia—findings from a controlled study. Eur Psychiatry 1999;14:118-131.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington: American Psychiatric Association Publishing;2013.
4. Pine DS, Klein KG. Anxiety disorders. In: Thapar A, Pine DS, McDonald N, Silverman WK. Salivary oxytocin in clinically anxious youth: associations with separation anxiety and family accommodation. Psychoneuroendocrinology 2016;65:33-43.
5. Stein DJ, Westenberg HG, Liebowitz MR. Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. J Clin Psychiatry 2002;63 Suppl 6:12-19.
6. Rauch SL, Shin LM, Wright CL. Neuroimaging studies of amygdala function in anxiety disorders. Ann N Y Acad Sci 2003;985:389-410.
7. Carson DS, Garner JP, Hyde SA, Libove RA, Berquist SW, Hornbeak KB, et al. Arginine vasopressin is a blood-based biomarker of social functioning in children with autism. PLoS One 2015;10:e013224.
8. Hoge EA, Pollack MH, Kaufman RE, Zak PJ, Simon NM. Oxytocin levels in social anxiety disorder. CNS Neurosci Ther 2008;14:165-170.
9. Oh KS, Kim EJ, Ha JW, Woo HY, Kwon MJ, Shin DW, et al. The relationship between plasma oxytocin levels and social anxiety symptoms. Psychiatric Investig 2018;15:1079-1086.
10. Guyton AC, Hall JE. Pituitary hormones and their control by the hypothalamus. In: Guyton AC, Hall JE, editors. Pocket companion to Guyton and Hall textbook of medical physiology. 11th ed. Philadelphia:Saunders/Elsevier;2006. p. 918-929.
11. Ludwig M, Leng G. Dendritic peptide release and peptide-dependent behaviours. Nat Rev Neurosci 2006;7:126-136.
12. Hall JE. Pocket companion to Guyton and Hall textbook of medical physiology. 13th ed. Philadelphia:Elsevier;2016. p.939-950.
13. Suzuki S, Fujisawa TX, Sakakibara N, Fujioka T, Takiguchi S, Tornoda A. Development of social attention and oxytocin levels in maltreated children. Sci Rep 2020;10:7-10.
14. Yoon S, Kim YK. The role of the oxytocin system in anxiety disorders. In: Kim YK, editor. Anxiety disorders: rethinking and understanding recent discoveries. Singapore:Springer;2020. p.103-120.
15. Neumann ID, Wigger A, Torner L, Holshoer F, Landgraf R. Brain oxytocin inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and female rats: partial action within the paraventricular nucleus. J Neuroendocrinol 2000;12:235-243.
16. Kirsch P. Oxytocin in the socioemotional brain: implications for psychiatric disorders. Dialogues Clin Neurosci 2015;17:463-476.
17. Hoge EA, Lawson EA, Metcalfe CA, Keshavih A, Zak PJ, Pollack MH, et al. Plasma oxytocin immunoreactive products and response to trust in patients with social anxiety disorder. Depress Anxiety 2012;29:924-930.
18. Liebowitz ER, Leckman JF, Feldman R, Zagoory-Sharon O, McDonald N, Silverman WK. Salivary oxytocin in clinically anxious youth: associations with separation anxiety and family accommodation. Psychoneuroendocrinology 2016;65:33-43.
19. Beidel DC, Turner SM. Shy children, phobic adults: nature and treatment of social anxiety disorder. 2nd ed. Arlington: American Psychiatric Association Publishing;2007.
20. Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci 2011;15:301-309.
21. Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, Heinrichs M, et al. Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. Int J Neuropsychopharmacol 2012;15:883-896.
22. Eapen V, Dadds M, Barnett B, Kohlhoff J, Khan F, Radom N, et al. Separation anxiety, attachment and inter-personal representations: disentangling the role of oxytocin in the perinatal period. PLoS One 2014;9:e107745.
23. Mitre M, Kranz TM, Marlin BJ, Schiado JK, Erdjument-Bromage H, Zhang X, et al. Sex-specific differences in oxytocin receptor expression and function for parental behavior. Gend Genome 2017;1:142-166.
24. Marazziti D, Baroni S, Mugci F, Piccinni A, Moroni I, Giannaccini G, et al. Sex-related differences in plasma oxytocin levels in humans. Clin Pract Epidemiol Ment Health 2019;15:58-63.
25. Caldwell HK. Oxytocin and sex differences in behavior. Curr Opin Behav Sci 2018;23:13-20.
26. Feng C, DeMarco AC, Haroon E, Rilling JK. Neuroticism modulates the effects of intranasal vasopressin treatment on the neural response to positive and negative social interactions. Neuropsychologia 2015;73:108-115.
27. Lukas M, Neumann ID. Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders. Behav Brain Res 2013;251:85-94.
28. Neumann ID, Landgraf R. Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci 2012;35:649-659.
29. Landgraf R, Neumann ID. Vasopressin and oxytocin release
within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol 2004;25:150-176.

30. Beiderbeck DJ, Neumann ID, Veenema AH. Differences in intermale aggression are accompanied by opposite vasopressin release patterns within the septum in rats bred for low and high anxiety. Eur J Neurosci 2007;26:3597-3605.

31. Blume A, Bosch OJ, Miklos L, Otten L, Wale L, Waldherr M, et al. Oxytocin reduces anxiety via ERK1/2 activation: local effect within the rat hypothalamic paraventricular nucleus. Eur J Neurosci 2008;27:1947-1956.

32. Huber D, Veinante P, Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 2005;308:243-248.

33. Ludwig M, Tobin VA, Callahan MF, Papadaki E, Becker A, Engemann M, et al. Intranasal application of vasoressin fails to elicit changes in brain immediate early gene expression, neural activity and behavioural performance of rats. J Neuroendocrinol 2013;25:655-667.

34. Heim C, Young LJ, Newport DJ, Mletzko T, Miller AH, Engelmann M, et al. Intranasal administration of oxytocin increases state anxiety and cortisol in women with a history of childhood abuse. Mol Psychiatry 2009;14:954-958.

35. Hersen M, Hilsenroth MJ, Segal DL. Comprehensive handbook of psychological assessment: volume 2: personality assessment. Hoboken:Wiley;2004.

36. Pacheco-Unguetti AP, Acosta A, Callejas A, Lupaianez J. Attention and anxiety: different attentional functioning under state and trait anxiety. Psychol Sci 2010;21:298-304.

37. Tofs M, van Peer JM, Kort J, Wijers AA, Tucker DM. Anxiety, cortisol, and attachment predict plasma oxytocin. Psychophysiology 2007;44:444-449.

38. Göldler B, Unal F, Pehlivanbutk B, Çengel Kütür E, Akdemir D, Taner Y. Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version-Turkish version (K-SADS-PL-T). Turk J Child Adolesc Ment Health 2004;11:109-116. Turkish.

39. Unal F, Öktem F, Çetin Çuhadaroğlu F, Çengel Kütür SE, Akdemir D, Foto Özdemir D, et al. [Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version-Turkish version (K-SADS-PL-T)]. Turk J Child Adolesc Psychiatry Neurosci 2012;319-333. Turkish.

40. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL: initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980-988.

41. Özy B. Çocuklar için depresnin ölçüsü: geçerlilik ve güvenilirlik çalışması. Turk Psikiyatr Derg 1991;2:132-136. Turkish.

42. Özusta Ş. [Validity and reliability of Turkish version of state-trait anxiety inventory for children]. Turk J Psychol 1995;10:32-44. Turkish.

43. Aslan SH, Alparslan ZN. [The reliability, validity and factor structure of the childhood trauma questionnaire among a group of university students]. Turk J Psychiatry 1999;10:275-285.

44. Demir T, Eralp Demir M, Türksoy N, Özmen E, Uysal O. [Validity and reliability of social phobia scale for children and adolescents]. Dusunen Adam J Psychiatry Neurol Sci 2000;13:42-48. Turkish.

45. Şişman S. [Turkish adaptation of behavioral inhibition system/behavioral activation system scales (BIS/BAS scales): validity and reliability studies]. Stud Psychol 2012;32:1-22.

46. Kovacs M. The children’s depression, inventory (CDI). Psychopharmacol Bull 1985;21:995-998.

47. Ivarsson T, Svalander P, Liljestein O. The children’s depression inventory (CDI) as measure of depression in Swedish adolescents. A normative study. Nord J Psychiatry 2006;60:220-226.

48. Spielberger CD, Edwards CD, Montuori J, Lushene R. State-trait anxiety inventory for children [Internet]. Menlo Park (CA): Mind Garden; 1970 [cited at 2020 Nov 24]. Available from: https://www.mindgarden.com/146-state-trait-anxiety-inventory-for-children.

49. Muris P, Merckelbach H, Ollendiek T, King N, Bogie N. Three traditional and three new childhood anxiety questionnaires: their reliability and validity in a normal adolescent sample. Behav Res Ther 2002;40:753-772.

50. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, et al. Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry 1994;151:1132-1136.

51. Bernstein DP, Ahluvalia T, Bogie N, Handelsman L. Validity of the childhood trauma questionnaire in an adolescent psychiatric population. J Am Acad Child Adolesc Psychiatry 1997;36:340-348.

52. La Greca A, Stone W. Social anxiety scale for children revised:factor structure and concurrent validity. J Clin Child Adolesc Psychol 1993;22:17-27.

53. Carver CS, White TL. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: the BIS/BAS scales. J Personal Soc Psychol 1994;67:319-333.

54. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: social neuro-peptides for translational medicine. Nat Rev Neurosci 2011;12:524-538.

55. Striepens N, Kendrick KN, Maier W, Hurlemann R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front Neuroendocrinol 2011;32:426-450.

56. Heinrichs M, Baumgartner T, Kirschbaum C, Ebler U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 2003;54:1389-1398.
57. Neumann ID, Slattery DA. Oxytocin in general anxiety and social fear: a translational approach. Biol Psychiatry 2016;79:213-221.

58. MacDonald K, MacDonald TM, Brüne M, Lamb K, Wilson MP, Golshan S, et al. Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression. Psychoneuroendocrinology 2013;38:2831-2843.

59. Weisman O, Zagoory-Sharon O, Feldman R. Oxytocin administration alters HPA reactivity in the context of parent-infant interaction. Eur Neuropsychopharmacol 2013;23:1724-1731.

60. Olff M, Frijling JL, Kuhlansky LD, Bradley B, Ellenbogen MA, Cardoso C, et al. The role of oxytocin in social bonding, stress regulation and mental health: an update on the moderating effects of context and interindividual differences. Psychoneuroendocrinology 2013;38:1883-1894.

61. Ein-Dor T, Verbeke WJMI, Mokry M, Vrtička P. Epigenetic modification of the oxytocin and glucocorticoid receptor genes is linked to attachment avoidance in young adults. Attach Hum Dev 2018;20:439-454.

62. Baker M, Lindell SG, Driscoll CA, Zhou Z, Yuan Q, Schwandt ML, et al. Early rearing history influences oxytocin receptor epigenetic regulation in rhesus macaques. Proc Natl Acad Sci USA 2017;114:11769-11774.

63. Clark DM, McManus F. Information processing in social phobia. Biol Psychiatry 2002;51:92-100.

64. Hezel DM, McNally RJ. Theory of mind impairments in social anxiety disorder. Behav Ther 2014;45:530-540.

65. Lawson EA, Holsen LM, Santin M, DeSanti R, Meenaghan E, Eddy KT, et al. Postprandial oxytocin secretion is associated with severity of anxiety and depressive symptoms in anorexia nervosa. J Clin Psychiatry 2013;74:e451-e457.

66. Krause S, Boeck C, Gumpf AM, Rottler E, Schury K, Karabatsiakis A, et al. Child maltreatment is associated with a reduction of the oxytocin receptor in peripheral blood mononuclear cells. Front Psychol 2018;9:173.

67. Kim TK, Lee JE, Kim JE, Park JY, Choe J, Kim H, et al. G9a-mediated regulation of OXT and AVP expression in the basolateral amygdala mediates stress-induced lasting behavioral depression and its reversal by exercise. Mol Neurobiol 2016;53:2843-2856.